Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
about
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
P2860
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@en
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@nl
type
label
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@en
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@nl
prefLabel
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@en
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@nl
P2093
P2860
P1476
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
@en
P2093
Katelijne De Nys
Kim Pauwels
Steven Simoens
P2860
P304
P356
10.1586/14737167.2015.1047347
P577
2015-05-15T00:00:00Z